Civil Society
- Increase access to affordable generic drugs for HIV/AIDS through compulsory licensing and increased market competition
- "Robust implementation" of WTO Paragraph 6 Decision
- Reduce bureaucratic complexity of CAMR and WTO Decision
- Reduce patent-holders’ ‘abusive litigation’ against generic companies
- Generic industry needs profit incentives
- Research-based industry is too profit-driven
- Political pressure exists on countries to avoid using WTO Decision

Developing Country Representatives
- Increase generic competition to further reduce antiretroviral therapy prices
- Address inadequate institutional infrastructure to allow use of WTO Decision
- Ensure adequate monitoring of "less than transparent" governments
- Political pressure exists on countries to avoid using WTO Decision

Generic Companies
- Increase affordable drug access in developing countries through low cost Canadian-made generics
- Avoid litigation from patent-holders
- Ensure high quality generic drugs for developing countries
- Reduce bureaucratic complexity of CAMR and WTO Decision
- No potential for profits exists under CAMR or the WTO Decision

Government
- Protect intellectual property to spur pharmaceutical innovation and strong domestic economy
- Promote public health and human rights in developing world by facilitating drug affordability in poor countries
- Increase funding to support programs and social development to address HIV/AIDS, tuberculosis and malaria
- Comply with international trade agreements

Research-based Industry
- Promote pharmaceutical innovation
- Encourage investment in pharmaceutical R&D through intellectual property protection
- Increase international aid, improve health system infrastructure and increase human resource capacity to improve drug access
- Comply with international trade agreements
- Prevent diversion of copied medicines back into profitable markets
- CAMR should not be non-profit